Events Archives - Page 29 of 128

1 minute read

Harpoon Therapeutics Abstract For HPN217 Accepted For Presentation At The 65th American Society Of Hematology Annual Meeting And Exposition

November 2, 9:26 AM

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed

HARP

3 minute read

Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of EDIT-301 At The ASH 2023 Annual Meeting And In A Company-Sponsored Webinar

By Benzinga Newsdesk

November 2, 9:25 AM

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ETDr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday, December 11CAMBRIDGE,

EDIT

4 minute read

Affimed Announces Oral Presentation Of Phase 1/2 Data From AFM13 In Combination With Allogeneic NK Cells At The 2023 ASH Annual Meeting

By Benzinga Newsdesk

November 2, 9:24 AM

In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a 72.2% complete

AFMD

3 minute read

Protagonist Therapeutics Announces Abstracts Selected For Oral And Poster Presentations At The American Society Of Hematology 2023 Annual Meeting

By Benzinga Newsdesk

November 2, 9:23 AM

Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the treatment of Polycythemia Vera and other disease

PTGX

6 minute read

Genmab Announces Multiple Abstracts To Be Presented At The 65th Annual Meeting And Exposition Of The American Society Of Hematology

By Benzinga Newsdesk

November 2, 9:23 AM

Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populationsOral presentations highlighting

GMAB

3 minute read

Eledon Reports Updated Data From Ongoing Phase 1b Trial Evaluating Tegoprubart For Prevention Of Rejection In Kidney Transplantation

By Benzinga Newsdesk

November 2, 9:22 AM

Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time

ELDN

7 minute read

Agios Pharmaceuticals To Present Broad Set Of Clinical And Translational Data In Rare Blood Disorders At 65th ASH Annual Meeting and Exposition

By Benzinga Newsdesk

November 2, 9:22 AM

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancement to Phase 3

AGIO

2 minute read

Vertex To Present New Data On Exagamglogene Autotemcel At The American Society Of Hematology Annual Meeting And Exposition

By Benzinga Newsdesk

November 2, 9:21 AM

- New data including longer duration follow-up from SCD and TDT pivotal trials accepted for oral presentation –- Five additional abstracts accepted for poster presentation -Vertex Pharmaceuticals Incorporated

VRTX

5 minute read

Multiple Clinical And Preclinical Presentations At ASH 2023 Highlight Vor Bio’s Novel eHSC And CAR-T Platform

By Benzinga Newsdesk

November 2, 9:20 AM

Three oral and two poster presentations accepted by ASH Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the

VOR

4 minute read

Shattuck Labs To Present Topline Data From Phase 1 A/B Clinical Trial Of SL-172154 In Relapsed/Refractory Acute Myeloid Leukemia And Higher-Risk Myelodysplastic Syndromes Patients At The ASH 2023 Annual Meeting

By Benzinga Newsdesk

November 2, 9:20 AM

– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) --

STTK